Company Overview and News

to your dashboard

Headline News

Alexion Pharma - Underperformance Does Not Equal Opportunity

8h seekingalpha
Both observations make it easy to avoid shares for now, even as they have been lagging for a while. (40-0)

Tracking John Paulson's Paulson & Company Portfolio - Q3 2017 Update

2017-11-18 seekingalpha
Paulson & Company's largest three positions are the SPDR Gold ETF, Shire plc, and Mylan NV. (1155-6)

Achillion (ACHN) Shares Down as J&J Announces Stake Sale

2017-11-15 zacks
Achillion Pharmaceuticals, Inc.’s (ACHN - Free Report) shares fell almost 7.9% in after-market trading on Tuesday, following the announcement that Johnson & Johnson’s (JNJ - Free Report) will sell its stake in the company. (91-0)

3 Big Stock Charts for Wednesday: Alexion Pharmaceuticals, Inc., Alliance Data Systems Corporation and Snap-on Incorporated | InvestorPlace

2017-11-15 investorplace
Stocks are heading for one of their worst weeks in while as traders continue to cash out of profitable positions, forcing prices lower. So far, the catalyst for the sell-off has been blamed on uncertainty about whether Congress will be able to move forward with the planned overhaul to our tax codes.  From our perspective though, this is more likely a case of getting out while the getting is good. (65-1)

'How do you put a price on somebody's life?': Student needs $750K to treat rare disorder

A B.C. student dying of a rare but treatable disorder says she’s in desperate need of financial help, because the only drug that might save her costs $750,000 a year. (40-0)

Short Sellers Grow More Selective on Major Biotechs

2017-11-10 247wallst
The short interest data are out for the most recent settlement date, October 31. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with big potential upside and big potential downside. The health care sector in general has rallied since Donald Trump won the presidency, but now that the fate of the ACA is uncertain, the health care rally is called into question. (287-2)

Tracking Dan Loeb's Third Point Portfolio - Q3 2017 Update

2017-11-10 seekingalpha
Dan Loeb's 13F portfolio value increased 5.45% from $11.28B to $11.90B this quarter. The number of positions increased from 32 to 37. (1016-2)

Sarepta Therapeutics Will Continue To Ride High On EXONDYS 51's Success In 2017

2017-11-08 seekingalpha
EXONDYS 51 is seeing rising demand, thanks to increasing adoption of genetic testing and higher patient compliance rates. (210-1)

Featured Company News - Japanese Patent Office Issued New Patent to Alexion Pharma's Soliris; Extending Patent Protection into 2027

2017-11-08 accesswire
LONDON, UK / ACCESSWIRE / November 8, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) ("Alexion"), following which we have published a free report that can be viewed by signing up at The Company announced on November 06, 2017, that it has received a new Patent, directed to the composition of matter of eculizumab (Soliris®) and pharmaceutical formulations of eculizumabby Japanese Patent Office (JPO), which will expire in 2027. (56-0)

Weak Sales Growth Drop Alexion Pharmaceuticals (ALXN) to Sell

2017-11-07 investorplace
Alexion Pharmaceuticals Inc (NASDAQ:ALXN) is a $26.3 billion in market value component of the Biotechnology GICS industry group where The current Portfolio Grader ranking for ALXN puts it 207 among the 349 companies in this industry group, which is a below-average position. ALXN is ranked in the third quartile of the sector with a ranking of 480 among the 785 companies in the sector and number 3,109 in the 5000 company Portfolio Grader company universe. (40-0)

Confirmatory Studies May Expand Uptake of Exondys 51

2017-11-06 marketrealist
Sarepta Therapeutics (SRPT) reported that by the end of 3Q17, all Tier 1 and Tier 2 sites, which will be treating around 75% of DMD (Duchenne muscular dystrophy) patients with mutations amenable to exon-51 skipping, had submitted start forms for Exondys 51 (eteplirsen). The company has also witnessed an increase in start forms submitted by Tier 3 sites. Also, by the end of 3Q17, around 160 independent physicians had submitted start forms for the drug. (77-0)

3 ETFs to Watch on Biotech Earnings

2017-11-06 investorplace
The earnings season is off to a flying start with equity markets scaling record highs, owing to a slew of upbeat economic data, strong corporate performance and President Donald Trump’s tax reform proposal. However, the performance has been a mixed bag for biotech companies, with some beating market expectations, while a few failing to do so. (164-0)

Achillion (ACHN) Q3 Loss Narrows, Pipeline Expansion in Focus

2017-11-04 zacks
Achillion Pharmaceuticals, Inc. (ACHN - Free Report) reported a loss of 14 cents per share in the third quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of 18 cents. In the year-ago quarter, the company had reported a loss of 15 cents per share. (118-0)

Sarepta Therapeutics Expects Robust Revenue Growth for 2017

2017-11-01 marketrealist
In its 3Q17 earnings conference call, Sarepta Therapeutics (SRPT) raised its 2017 revenue guidance from the previously projected range of $125 million–$130 million to $150 million–$155 million. Its Duchenne muscular dystrophy (or DMD) drug Exondys 51 reported revenues close to $46 million, which was significantly higher than what Wall Street projected. (84-0)

Patisiran Expected to Become Key Growth Driver for Alnylam

2017-10-31 marketrealist
Alnylam Pharmaceuticals’ (ALNY) investigational drug Patisiran is expected to target 20,000 to 30,000 patients with hereditary ATTR (or hATTR) amyloidosis with polyneuropathy caused by amyloid deposition in nerves. A significant portion of these patients also demonstrate cardiomyopathy or amyloid deposition in the heart and are considered to be mixed phenotype patients. Since the neuropathy is also related to all types of nerves and can result in loss of sensory, motor, and autonomic function, hATTR amyloidosis is considered to be a rare yet debilitating and fatal genetic condition. (63-0)

CUSIP: 015351909